Downregulation of ER60 Protease Inhibits Cellular Proliferation by Inducing G1/S Arrest in Breast Cancer Cells In Vitro

Anatomical Record

Volumn 295, Issue 3, 2012, Pages 410-416

  Lwin, Zin Mar ^a   Yip, George Wai Cheong ^a   Chew, Fook Tim ^a   Bay, Boon Huat ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Breast cancer; Endoplasmic reticulum; ER60; Gene silencing

Indexed keywords

ER60 PROTEASE; MESSENGER RNA; PROTEINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE SEQUENCE; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; M PHASE CELL CYCLE CHECKPOINT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; S PHASE CELL CYCLE CHECKPOINT; WESTERN BLOTTING;

BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; G1 PHASE; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; PROTEIN DISULFIDE-ISOMERASES; RNA INTERFERENCE; S PHASE; S PHASE CELL CYCLE CHECKPOINTS;

EID: 84857038981     PISSN: 19328486     EISSN: 19328494     Source Type: Journal    
DOI: 10.1002/ar.22413     Document Type: Article

References (43)

1. Apati A, Janossy J, Brozik A, Bauer PI, Magocsi M. 2003. Calcium induces cell survival and proliferation through the activation of the MAPK pathway in a human hormone-dependent leukemia cell line, TF-1. J Biol Chem 278: 9235-9243.
2. Ayshamgul H, Ma H, Ilyar S, Zhang LW, Abulizi A. 2011. Association of defective HLA-I expression with antigen processing machinery and their association with clinicopathological characteristics in Kazak patients with esophageal cancer. Chin Med J (Engl) 124: 341-346.
3. Bennett CF, Balcared JM, Varrichio A, Crooke ST. 1988. Molecular cloning and complete amino-acid sequence of form-I phosphoinositide-specific phospholipase C. Nature 334: 268-270.
4. Borges S, Moudilou E, Vouyovitch C, Chiesa J, Lobie P, Mertani H, Raccurt M. 2008. Involvement of a JAK/STAT pathway inhibitor: cytokine inducible SH2 containing protein in breast cancer. Adv Exp Med Biol 617: 321-329.
5. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
6. Castaneda CA, Cortes-Funes H, Gomez HL, Ciruelos EM. 2010. The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer. Cancer Metastasis Rev 29: 751-759.
7. Celli CM, Jaiswal AK. 2003. Role of GRP58 in mitomycin C-induced DNA cross-linking. Cancer Res 63: 6016-6025.
8. Chapman DC, Williams DB. 2010. ER quality control in the biogenesis of MHC class I molecules. Semin Cell Dev Biol 21: 512-519.
9. Cicchillitti L, Di Michele M, Urbani A, Ferlini C, Donat MB, Scambia G, Rotilio D. 2009. Comparative proteomic analysis of paclitaxel sensitive A2780 epithelial ovarian cancer cell line and its resistant counterpart A2780TC1 by 2D-DIGE: the role of ERp57. J Proteome Res 8: 1902-1912.
10. Coe H, Jung J, Groenendyk J, Prins D, Michalak M. 2010. ERp57 modulates STAT3 signaling from the lumen of the endoplasmic reticulum. J Biol Chem 285: 6725-6738.
11. Coe H, Michalak M. 2010. ERp57, a multifunctional endoplasmic reticulum resident oxidoreductase. Int J Biochem Cell Biol 42: 796-799.
12. Corazzari M, Lovat PE, Armstrong JL, Fimia GM, Hill DS, Birch-Machin M, Redfern CP, Piacentini M. 2007. Targeting homeostatic mechanisms of endoplasmic reticulum stress to increase susceptibility of cancer cells to fenretinide-induced apoptosis: the role of stress proteins ERdj5 and ERp57. Br J Cancer 96: 1062-1071.
13. Deeb KK, Trump DL, Johnson CS. 2007. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 7: 684-700.
14. Dunn GP, Koebel CM, Schreiber RD. 2006. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6: 836-848.
15. Garbi N, Hammerling G, Tanaka S. 2007. Interaction of ERp57 and tapasin in the generation of MHC class I-peptide complexes. Curr Opin Immunol 19: 99-105.
16. Hery C, Ferlay J, Boniol M, Autier P. 2008. Changes in breast cancer incidence and mortality in middle-aged and elderly women in 28 countries with Caucasian majority populations. Ann Oncol 19: 1009-1018.
17. Hsiao YH, Chou MC, Fowler C, Mason JT, Man YG. 2010. Breast cancer heterogeneity: mechanisms, proofs, and implications. J Cancer 1: 6-13.
18. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CA Cancer J Clin 61: 69-90.
19. Khanal RC, Nemere I. 2007a. Membrane receptors for vitamin D metabolites. Crit Rev Eukaryot Gene Expr 17: 31-47.
20. Khanal RC, Nemere I. 2007b. The ERp57/GRp58/1, 25D3-MARRS receptor: multiple functional roles in diverse cell systems. Curr Med Chem 14: 1087-1093.
21. Kim EK, Choi EJ. 2010. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 1802: 396-405.
22. Koumenis C. 2006. ER stress, hypoxia tolerance and tumor progression. Curr Mol Med 6: 55-69.
23. Kurzawa L, Morris MC. 2010. Cell-cycle markers and biosensors. ChemBioChem 11: 1037-1047.
24. Lacroix M, Leclercq G. 2004. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 83: 249-289.
25. Leys CM, Nomura S, LaFleur BJ, Ferrone S, Kaminishi M, Montgomery E, Goldenring JR. 2007. Expression and prognostic significance of prothymosin-alpha and ERp57 in human gastric cancer. Surgery 141: 41-50.
26. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method. Methods 25: 402-408.
27. Lord BI. 1986. Controls on the cell cycle. Int J Radiat Biol Relat Stud Phys Chem Med 49: 279-296.
28. Matsuda T, Marugame T, Kamo KI, Katanoda K, Ajiki W, Sobue T. 2011. Cancer incidence and incidence rates in Japan in 2005: based on data from 12 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) Project. Jpn J Clin Oncol 41: 139-147.
29. Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren GJ. 2008. Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother 57: 197-206.
30. National Registry of Diseases Office of Singapore. Available at: Accessed on 15 March 2011.
31. Ni M, Lee AS. 2007. ER chaperones in mammalian development and human diseases. FEBS Lett 581: 3641-3651.
32. Otsu M, Urade R, Kito M, Omura F, Kikuchi M. 1995. A possible role of ER-60 protease in the degradation of misfolded proteins in the endoplasmic reticulum. J Biol Chem 270: 14958-14961.
33. Qi YJ, He QY, Ma YF, Du YW, Liu GC, Li YJ, Tsao GS, Ngai SM, Chiu JF. 2008. Proteomic identification of malignant transformation-related proteins in esophageal squamous cell carcinoma. J Cell Biochem 104: 1625-1635.
34. 3-MARRS (membrane associated, rapid response steroid-binding), a novel vitamin D receptor, in growth inhibition of breast cancer cells. Exp Cell Res 316: 695-703.
35. Seliger B, Ritz U, Abele R, Bock M, Tampe R, Sutter G, Drexler I, Huber C, Ferrone S. 2001. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res 61: 8647-8650.
36. Seliger B, Stoehr R, Handke D, Mueller A, Ferrone S, Wullich B, Tannapfel A, Hofstaedter F, Hartmann A. 2010. Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. Cancer Immunol Immunother 59: 529-540.
37. Spano JP, Milano G, Rixe C, Fagard R. 2006. JAK/STAT signalling pathway in colorectal cancer: a new biological target with therapeutic implications. Eur J Cancer 42: 2668-2670.
38. Tanaka T, Kuramitsu Y, Fujimoto M, Naito S, Oka M, Nakamura K. 2008. Downregulation of two isoforms of ubiquitin carboxyl-terminal hydrolase isozyme L1 correlates with high metastatic potentials of human SN12C renal cell carcinoma cell clones. Electrophoresis 29: 2651-2659.
39. Tartaglia M, Gelb BD. 2010. Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms. Ann NY Acad Sci 1214: 99-121.
40. Urade R, Kito M. 1992. Inhibition by acidic phospholipids of protein degradation by ER-60 protease, a novel cysteine protease, of endoplasmic reticulum. FEBS Lett 312: 83-86.
41. Urade R, Kusunose M, Moriyama T, Higasa T, Kito M. 2000. Accumulation and degradation in the endoplasmic reticulum of a truncated ER-60 devoid of C-terminal amino acid residues. J Biochem 127: 211-220.
42. Vigneron N, Peaper DR, Leonhardt RM, Cresswell P. 2009. Functional significance of tapasin membrane association and disulfide linkage to ERp57 in MHC class I presentation. Eur J Immunol 39: 2371-2376.
43. Vuong DA, Velasco-Garrido M, Lai TD, Busse R. 2010. Temporal trends of cancer incidence in Vietnam, 1993-2007. Asian Pac J Cancer Prev 11: 739-745.